tiprankstipranks
Trending News
More News >
Mega Genomics Limited (HK:6667)
:6667
Hong Kong Market

Mega Genomics Limited (6667) Price & Analysis

Compare
0 Followers

6667 Stock Chart & Stats


Financials

6667 FAQ

What was Mega Genomics Limited’s price range in the past 12 months?
Mega Genomics Limited lowest stock price was HK$5.98 and its highest was HK$10.98 in the past 12 months.
    What is Mega Genomics Limited’s market cap?
    Mega Genomics Limited’s market cap is HK$1.61B.
      When is Mega Genomics Limited’s upcoming earnings report date?
      Mega Genomics Limited’s upcoming earnings report date is Aug 28, 2025 which is in 58 days.
        How were Mega Genomics Limited’s earnings last quarter?
        Currently, no data Available
        Is Mega Genomics Limited overvalued?
        According to Wall Street analysts Mega Genomics Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Mega Genomics Limited pay dividends?
          Mega Genomics Limited does not currently pay dividends.
          What is Mega Genomics Limited’s EPS estimate?
          Mega Genomics Limited’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Mega Genomics Limited have?
          Mega Genomics Limited has 224,300,200 shares outstanding.
            What happened to Mega Genomics Limited’s price movement after its last earnings report?
            Currently, no data Available
            Which hedge fund is a major shareholder of Mega Genomics Limited?
            Currently, no hedge funds are holding shares in HK:6667

            Mega Genomics Limited Stock Smart Score

            2
            Underperform
            1
            2
            3
            4
            5
            6
            7
            8
            9
            10

            Technicals

            SMA
            Negative
            20 days / 200 days
            Momentum
            -26.45%
            12-Months-Change

            Fundamentals

            Return on Equity
            4.87%
            Trailing 12-Months
            Asset Growth
            12.73%
            Trailing 12-Months

            Company Description

            Mega Genomics Limited

            Mega Genomics Limited, a genetic testing platform company, provides consumer genetic testing and cancer screening services in China. It offers general testing services comprising ApoE gene testing package that assesses the lipid metabolism capacity and the risk for various related diseases, including Alzheimer's disease; folate metabolic capacity assessment, which analyzes genes related to folate metabolism capacity to determine the risk of developing hyperhomocysteinemia, cardiovascular, and cerebrovascular diseases; Parkinson's disease risk assessment; full-scale cancer risk assessment package; and cardiovascular and cerebrovascular disease risk assessment package. The company also provides advanced testing services, which include Hereditary breast cancer/ovarian cancer genetic testing, Septin9 colorectal cancer screening test, and RNF180/Septin9 gastric cancer screening test; and executive testing services, such as personal whole genome test and whole-exome sequencing package for adults. It offers testing services through self-developed laboratory-developed tests and In-vitro diagnostics testing kits. The company serves health checkup centers, hospitals, and various other customers. Mega Genomics Limited was founded in 2016 and is based in Beijing, China.
            Similar Stocks
            Company
            Price & Change
            Follow
            Frontage Holdings Corp.
            Sisram Medical Ltd.
            TOT BIOPHARM International Co. Ltd.
            Chaoju Eye Care Holdings Ltd.
            Town Health International Medical Group Ltd.
            Popular Stocks
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis